WuXi Biologics wins FDA clearance for key manufacturing facility
By: IPP Bureau
Last updated : July 13, 2026 6:09 pm
The company has announced that its MFG8 drug substance manufacturing facility in Hebei successfully passed a US FDA Pre-License Inspection (PLI)
WuXi Biologics has cleared a major regulatory hurdle in the US, strengthening its role in the commercial production of a potential blockbuster autoimmune therapy.
The company has announced that its MFG8 drug substance manufacturing facility in Hebei successfully passed a US FDA Pre-License Inspection (PLI).
The successful outcome reinforces WuXi Biologics’ global regulatory standing and highlights its manufacturing capabilities, GMP execution standards, and commitment to delivering reliable biologics supply for markets worldwide.
The approval marks another milestone for WuXi Biologics’ expanding global manufacturing network. MFG8 is equipped with twelve 4,000L single-use bioreactors and uses the company’s “scale-out” manufacturing strategy, enabling flexible commercial production ranging from 4,000L to 20,000L.
The facility also incorporates advanced sustainability and digital technologies, including smart manufacturing platforms and a rooftop photovoltaic system designed to support carbon reduction, resource efficiency, and recycling initiatives.
Chris Chen, CEO of WuXi Biologics, said: "MFG8's successful FDA Pre-License Inspection pass is a strong testament to WuXi Biologics' commitment to global quality and compliance standards. This PLI pass reflects our sustained investment in a world-class quality system and our proven capability to support partners in advancing global commercial manufacturing.
"We are pleased to help bring this potential blockbuster autoimmune therapy to patients through our high-quality manufacturing capabilities. Moving forward, WuXi Biologics will continue to empower global partners with a reliable quality system and accelerate the delivery of innovative biologics to more patients worldwide."
The FDA milestone adds to WuXi Biologics’ growing record of regulatory achievements. By the end of 2025, the company had successfully completed 46 regulatory inspections, including 22 from the FDA and European Medicines Agency (EMA), and obtained 136 facility license approvals.